← Eichor
Condition: Lymphoma Diffuse Large B Cell Synced from ClinicalTrials.gov · July 30, 2026

Recruiting studies: Lymphoma Diffuse Large B Cell

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
Phase 1/Phase 2 · 2 location(s) · University Hospital Heidelberg · NCT03676504Comparison of Point-of-care Produced CAR T-cell with Commercial CAR T-cells in Patients with R/R LBCL
Phase 2 · 7 location(s) · University Medical Center Groningen · NCT05641428PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell Lymphoma
Phase N/A · 1 location(s) · Ruijin Hospital · NCT06755775Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
Phase 2 · 1 location(s) · John Lister · NCT05281809Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression
Phase 2 · 1 location(s) · Huazhong University of Science and Technology · NCT06005870Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
Phase 1/Phase 2 · 25 location(s) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · NCT06829771Orelabrutinib Combined With Standard Immunochemotherapy With or Without Autologous Hematopoietic Stem Cell Transplantati
Phase 2 · 1 location(s) · The Affiliated Hospital of Xuzhou Medical University · NCT07680933Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Phase 1/Phase 2 · 2 location(s) · Yazeed Sawalha · NCT06536049Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06570447Is Trogocytosis a Predictive Marker of CAR-T Cell Response in Diffuse Large B-cell Lymphoma?
NA · 2 location(s) · University Hospital, Montpellier · NCT06352242Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+
Phase 1 · 1 location(s) · University of Utah · NCT06227026A Non-interventional, International, Multicentre Clinical Research Study to Build the Largest Collection of Multimodal D
Phase N/A · 5 location(s) · OWKIN · NCT06625203B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide
Phase 1 · 1 location(s) · Mayo Clinic · NCT06191887Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treat
Phase 2 · 1 location(s) · University of California, Davis · NCT06905509Study of the Hematopoietic Niche and the Role of Inflammation in the Pathophysiology of Cytopenias After CAR-T Cell Ther
Phase N/A · 1 location(s) · Instituto de Investigación Biomédica de Salamanca · NCT06439173Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma
Phase 2 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT07078500Molecular Mechanisms in Malignant Lymphoma- Predict (MMML Predict)
Phase N/A · 1 location(s) · University Medical Center Goettingen · NCT06526065Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or
EARLY_Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT04512716Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus
Phase 3 · 20 location(s) · Beijing InnoCare Pharma Tech Co., Ltd. · NCT06521255A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
Phase 1/Phase 2 · 22 location(s) · Merck Sharp & Dohme LLC · NCT07519772Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
Phase 2 · 1 location(s) · New York Medical College · NCT02393157Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL
NA · 1 location(s) · Zhejiang Cancer Hospital · NCT06832267Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07255963Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Phase 1 · 4 location(s) · Newave Pharmaceutical Inc · NCT04775745Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL.
Phase 2 · 1 location(s) · Kim, Seok Jin · NCT04627753Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas
Phase 1 · 1 location(s) · Abramson Cancer Center at Penn Medicine · NCT07478848Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in Fir
Phase 1/Phase 2 · 1 location(s) · Stichting Hemato-Oncologie voor Volwassenen Nederland · NCT03356054Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Phase 2 · 82 location(s) · Allogene Therapeutics · NCT06500273Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R)
Phase 2 · 1 location(s) · University of Washington · NCT07097363Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies
NA · 1 location(s) · Medical University of Gdansk · NCT07270263
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.